Select Language
Transferrin R
Transferrin R Overview
| English Name | Transferrin receptor protein 1 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 15 | Target Synonym | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Highest Development Stage | Approved | ||
| English Name | Transferrin receptor protein 1 |
| Target Synonym | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 15 |
| Highest Development Stage | Approved |
Transferrin R Product List
- Product Category
Protein (16)Cell (1)
- Product Status
Launched (17)
- Species
Human (7)Cynomolgus (4)Mouse (4)Rat (2)
- Tag
His Tag (7)His Tag & Avi Tag (4)Fc Tag (3)Tag Free (2)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (8)Biotin-labeled (8)- (1)
Total: 17
- 1
- 2
Transferrin R Background
CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.
Transferrin R Synonyms
CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | beta-Thalassemia; Iron Metabolism Disorders | Details | |
| Delpacibart braxlosiran | AOC1020 | Phase 3 Clinical | Avidity Biosciences Inc | Foot-and-Mouth Disease; Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral | Details |
| Delpacibart eteddesiran | AOC-1001; AOC 1001 | Phase 3 Clinical | Avidity Biosciences Inc | Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Muscular Atrophy; Muscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Musculoskeletal Diseases; Myotonia; Myotonic Disorders; Myotonic Dystrophy; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases | Details |
| Trontinemab | RO-7126209; RG-6102 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
| CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours | Details |
| Zeleciment rostudirsen | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
| AOC-1044 | AOC-1044; AOC 1044 | Phase 2 Clinical | Avidity Biosciences Inc | Muscular Dystrophy, Duchenne | Details |
| JR-446 | JR-446 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd, Medipal Holdings Corp | Mucopolysaccharidosis III | Details |
| JR-441 | JR-441 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis III | Details |
| Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
| PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
| INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| PRX012-TfR | PRX012-TfR | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
Product Reviews
***a2026-05-29
0People LikeWas purchased for use in BLI, both for immobilization onto human fc binding sensors and as analyte with a biotin-labeled TfR-targeting nanobody on streptavidin. Retested for use after 1.5 years storage at -80 and still had full functional activity.- S*** 2025-11-18 0People LikeUsed this material as a captured ligand in routine SPR testing on a Biacore. Material is clean, consistent, and easy to work with, and can be used to generate quality data
- ZZ2022-10-11 0People LikeWe needed this product for our antibody research. ACRO managed to get it to us much faster than we expected, which made our research work very accurate. cd71 is a potential new target in human leukemia and lymphoma cases. cd71 /TFRC / TfR has been shown to interact with GABARAP and HFE. I am very pleased with the product and the quick technical support.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호